In production, the company utilizes the latest advances in biotechnology, nanotechnology, medical engineering, and experimental new shrinkable plastics, memory metals, and other materials.
What was lacking, until now, was a safe and effective delivery instrument that could implant therapeutic agents within the heart, including both left and right ventricles, without the need for expensive and risky invasive cardiac procedures. Long-duration procedures endanger the patient through risk of complications, inconsistent results and high costs.
Boston TransTec designs, manufactures and sells a multifunctional injection catheter for the treatment and cure of cardiovascular pathologies, gastrointestinal, urogenital, pulmonary and other systems. The first product being introduced will be the Viper™ Multifunctional Injection Catheter that performs various diagnostic procedures safely, and delivers a variety of therapeutics (drugs, stem cells, polymers, biogels, nanoparticles, etc.) effectively into different organs. We will launch our business by first restoring cardiac functionality, stop degradation into heart failure or treat it to halt its progress, and improve patient quality of life.
This device has been successfully tested on animals in the best US medical centers: Pennsylvania, Columbia, and Harvard Universities. Four letters of intent have been received to purchase the Viper™ immediately upon production; initial annual revenue from these buyers would be over $10 million annually with following exponential increases.
The market potential for a minimally invasive, reliable and effective method for delivering therapeutic agents to the heart muscle and other organs is large. Our product is designed as a minimally invasive catheter-based delivery device to be used with existing treatment modalities, and for new treatments with drug, biopolymers, nanoparticles, or gene and stem cell regenerative therapies.
The market for the Viper™ Catheter has developed internationally and is just beginning to develop in the US. The stem cell market has grown from zero in the last three years; analysts at the Stem Cell Summit 2008 forecast its growth to $8.5 billion over the next decade (58% CAGR per year). The Viper™ Catheter will be marketed initially for cardiac applications and the company enjoys an excellent IP position from which derivative catheters and devices can be for other internal organs and associated pathologies.
Distinctive, deformable needle design reduces risk of wall perforation or damage during needle extension, enables injection into thin walls, and ensures homogenous distribution of injectates.
Stable contact with target tissue enables accurate intra-organ delivery and full retention of the injectate.
Self-sealing effect post-injection. Contracting tissue shuts the needle channels and traps the agent inside the injection site. This is critical when the injectate is potentially dangerous (polymers or hydrogels, in gene therapy using virus vectors, etc.).
Multifunctional construction enables multiple procedures without needing to re-insert other catheters or guidewires. Can be used for a broad variety of applications. No need for sophisticated assistive technologies. Reduces procedural radiation exposure for patients and doctors. Can be used with portable ultrasound devices alone or X-ray equipment.
180-degree maneuverability allows operator wide-range of steerability without the need to reposition the entire catheter, saving time and reducing risk of tissue damage.
Displays vital signs (systolic/diastolic/mean pressures, heart rate) which allows the operator to monitor the catheter’s location and optimal contact with organ wall. The operator is able to monitor patient status and intervene immediately if something goes wrong. The operator is notified when the catheter tip enters the art, when it comes in contact with the heart wall, and whether the tip has remained in contact for the entire duration of the delivery.
Direct insertion into the patient abolishes the need for a guide wire or other pre-catheterization procedures. Simplifies the insertion and maneuverability inside an organ.
Procedures completed in 10-20 minutes without general anesthesia versus 1+ hours with a conventional catheter. It takes 3 seconds to navigate the Viper™ Catheter from the femoral vessel in the groin to the heart’s ventricle. Patients can return home the same day.
Affordable and economical. The device itself is priced affordably, and its multifunctionality eliminates the need to purchase multiple other tools/equipment.
Easy to learn and use, as the Viper™ Catheter doesn’t require special training. It is intuitive to use and smooth to operate.
Delivery device and diagnostic tool. In addition to delivery applications, the Viper™ Catheter can perform various diagnostic procedures, eliminating the need for other diagnostic catheters and guide wires. It performs angiography of coronary or other vessels; ventriculography; enables biopsy, ultrasonography, visual observation, and others.
We are actively seeking collaborative opportunities with strategic partners and investors. If you're interested in exploring our technology, we invite you to reach out to discuss further.
The Viper™ Catheter is currently limited by United States law to investigational use and is not approved for sale or commercial use at this time.
